Respiratory Syncytial Virus

Programs can take several forms, including on-site clinics, voucher programs, and in-store events

RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.

Shared clinical decision-making presented drawbacks, resulting in age-based recommendations for adults aged 75 years and older and risk-based recommendations for individuals aged 60-74 years.

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

Individuals with chronic conditions like asthma, diabetes, and chronic obstructive pulmonary disease face an increased risk of developing RSV.

The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides key takeaways and advice to pharmacists on the administration of RSV vaccines.

An expert on RSV vaccination provides insights on barriers that prevent the uptake of RSV vaccines and preventative measure in the pipeline for RSV.

Educate patients about the importance of vaccination in preventing severe disease.

Providing immunization coadministration and assisting with insurance coverage are strategies to improve access.

Understanding preventive care reduces the risk of illnesses and decreases future costs.

Focusing on the preparation of RSV vaccines, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides detailed insights on the differences between the adjuvanted and nonadjuvanted vaccines.

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, outlines evidence-based measures that can be implemented to prevent or minimize the transmission of RSV.

Differentiating between the 3 available options can help identify which is best for individual patients.

An expert on RSV discusses symptoms that warrant emergent medical care and the overall impact of RSV on older adults or immunocompromised individuals.

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides an overview of respiratory syncytial virus (RSV), highlighting disease transmission, incidence, symptoms, and factors that indicate higher risk of hospitalization.

Pharmacists’ awareness of respiratory syncytial virus and their role in educating about the vaccine have grown dramatically.

Carrie Koenigsfeld, PharmD, FAPhA, shares strategies that pharmacists can use to effectively tackle vaccine hesitancy, particularly concerning newer vaccines such as the RSV vaccine, through building trust with patients to encourage informed decision-making.

A medical expert examines the ideal timing for administering RSV vaccines to adults over 60 or pregnant women, emphasizing the importance of proper timing for a single-dose vaccine and outlining the necessary steps to be taken if a pregnant woman inadvertently receives an adjuvanted RSV vaccine.

The ACIP recommendations are designed to improve access to RSV vaccination, emphasizing the need to get vaccinated.

Carrie Koenigsfeld, PharmD, FAPhA, explores the potential contraindications that may preclude individuals from receiving an RSV vaccine.

Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.

Experts give important background information on respiratory syncytial virus (RSV), as well as the key clinical considerations that are associated with RSV vaccine use.

Experts give important background information on respiratory syncytial virus (RSV), as well as the key clinical considerations that are associated with RSV vaccine use.

The recent approval could further the use of mRNA technology across other indications.